Summary:
A Phase 3 Study in Subjects with Relapsing Remitting Multiple Sclerosis to Evaluate the Tolerability of ALKS 8700 and Dimethyl Fumarate
Qualified Participants Must:
Male and female adults aged 18 to 65 years
Has a confirmed diagnosis of RRMS
Qualified Participants May Receive:
Compensation for time and travel